Try our beta test site

Study of Proteins in Head and Neck Cancer Cells

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
NCT00896948
First received: May 9, 2009
Last updated: March 10, 2017
Last verified: March 2017

May 9, 2009
March 10, 2017
May 2005
Not Provided
  • Function and mechanism of LZAP in regulating ARF
  • Mechanism and biological consequences of LZAP inhibition of NF-κB
  • Determination of LZAP tumor suppressor activity
Same as current
Complete list of historical versions of study NCT00896948 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Proteins in Head and Neck Cancer Cells
Novel Protein Regulator of Tumor Suppressor ARF & NF-κB

RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at proteins in head and neck cancer cells.

OBJECTIVES:

  • Define the function and mechanism of LZAP in regulating ARF.
  • Determine the mechanism and biological consequences of LZAP inhibition of NF-κB.
  • Determine if LZAP has tumor suppressor activity by conditional targeting of LZAP in mice.

OUTLINE: Using molecular laboratory techniques, this study examines the biochemical mechanisms by which LZAP activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of ARF and inhibits transcriptional, tumorigenic activity of NF-kB. LZAP regulation of newly identified ARF activities, such as S-phase delay and ARF-mediated B23 degradation are also evaluated. LZAP's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target LZAP in mice and to observe for spontaneous and induced tumor formation. Laboratory analyses used to determine study endpoints include standard recombinant DNA, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, TUNEL assay, ELISA assay, Southern blotting, and protein and gene expression.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Head and Neck Cancer
  • Genetic: Southern blotting
  • Genetic: TdT-mediated dUTP nick end labeling assay
  • Genetic: gene expression analysis
  • Genetic: protein expression analysis
  • Other: flow cytometry
  • Other: fluorescent antibody technique
  • Other: immunoenzyme technique
  • Other: immunohistochemistry staining method
  • Other: immunologic technique
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Head and neck cancer tumor cell line

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
up to 120 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00896948
CDR0000558974
P30CA068485 ( US NIH Grant/Contract Award Number )
VU-VICC-HN-0529
VU-VICC-IRB-050259
Not Provided
Not Provided
Not Provided
Not Provided
Vanderbilt University Medical Center
Vanderbilt University Medical Center
National Cancer Institute (NCI)
Study Chair: Wendell G. Yarbrough, MD, FACS Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP